MEF2B

Source: Wikipedia, the free encyclopedia.
BORCS8-MEF2B
Available structures
PDBHuman UniProt search: PDBe RCSB
Identifiers
AliasesBORCS8-MEF2B, LOC729991-MEF2B, MEF2B, MEF2BNB-MEF2B, BORCS8-MEF2B readthrough, RSRFR2
External IDsGeneCards: BORCS8-MEF2B
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_005919

n/a

RefSeq (protein)

NP_001139257
NP_001354211
NP_005910.1

n/a

Location (UCSC)n/an/a
PubMed search[1]n/a
Wikidata
View/Edit Human

Myocyte enhancer binding factor 2B (MEF2B) is a transcription factor part of the MEF2 gene family including MEF2A, MEF2C, and MEF2D.[2][3] However, MEF2B is distant from the other three branches of MEF2 genes as it lacks the protein-coding Holliday junction recognition protein C-terminal (HJURP_C) region in vertebrates.[4]

Functions

The MEF2 gene family is expressed in muscle-specific gene activation and maintenance during development.[4][5] MEF2B mRNA is present in skeletal, smooth, brain and heart muscles.[6] MEF2B is directly involved in smooth muscle myosin heavy chain (SMHC) gene regulation. Overexpression of MEF2B will activate the SMHC promoter in smooth muscle when it is bound to the A/T-rich element of the promoter.[6]

Interactions

MEF2B has been shown to interact with CABIN1.[7][8]

Clinical relevance

Recurrent mutations in this gene have been associated with cases of diffuse large B-cell lymphoma.[9] In its mutated form, MEF2B can lead to deregulation of the proto-oncogene BCL6 expression in diffuse large B-cell lymphomas (DLBCL).[10] Mutations of MEF2B enhance its transcriptional activity due to either a disruption with its corepressor CABIN1 or causing the gene to become insensitive to inhibitory signaling events.[10]

See also

References

  1. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  2. ^ Krenács, Dóra; Borbényi, Zita; Bedekovics, Judit; Méhes, Gábor; Bagdi, Enikő; Krenács, László (2015-09-01). "Pattern of MEF2B expression in lymphoid tissues and in malignant lymphomas" (PDF). Virchows Archiv. 467 (3): 345–355. doi:10.1007/s00428-015-1796-6. ISSN 1432-2307. PMID 26089142. S2CID 25535467.
  3. ^ Rodríguez, Andrés I.; Csányi, Gábor; Ranayhossaini, Daniel J.; Feck, Douglas M.; Blose, Kory J.; Assatourian, Lillian; Vorp, David A.; Pagano, Patrick J. (2015-02-01). "MEF2B-Nox1 signaling is critical for stretch-induced phenotypic modulation of vascular smooth muscle cells". Arteriosclerosis, Thrombosis, and Vascular Biology. 35 (2): 430–438. doi:10.1161/ATVBAHA.114.304936. ISSN 1524-4636. PMC 4409426. PMID 25550204.
  4. ^ a b Wu, Wenwu; de Folter, Stefan; Shen, Xia; Zhang, Wenqian; Tao, Shiheng (2011-01-01). "Vertebrate paralogous MEF2 genes: origin, conservation, and evolution". PLOS ONE. 6 (3): e17334. Bibcode:2011PLoSO...617334W. doi:10.1371/journal.pone.0017334. ISSN 1932-6203. PMC 3048864. PMID 21394201.
  5. ^ Buchberger, A.; Arnold, H. H. (1999-06-01). "The MADS domain containing transcription factor cMef2a is expressed in heart and skeletal muscle during embryonic chick development". Development Genes and Evolution. 209 (6): 376–381. doi:10.1007/s004270050267. ISSN 0949-944X. PMID 10370120. S2CID 2819535.
  6. ^ a b Katoh, Y.; Molkentin, J. D.; Dave, V.; Olson, E. N.; Periasamy, M. (1998-01-16). "MEF2B is a component of a smooth muscle-specific complex that binds an A/T-rich element important for smooth muscle myosin heavy chain gene expression". The Journal of Biological Chemistry. 273 (3): 1511–1518. doi:10.1074/jbc.273.3.1511. ISSN 0021-9258. PMID 9430690.
  7. ^ Han A, Pan F, Stroud JC, Youn HD, Liu JO, Chen L (Apr 2003). "Sequence-specific recruitment of transcriptional co-repressor Cabin1 by myocyte enhancer factor-2". Nature. 422 (6933): 730–4. Bibcode:2003Natur.422..730H. doi:10.1038/nature01555. PMID 12700764. S2CID 4430658.
  8. ^ Youn HD, Sun L, Prywes R, Liu JO (Oct 1999). "Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2". Science. 286 (5440): 790–3. doi:10.1126/science.286.5440.790. PMID 10531067.
  9. ^ Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. (Aug 2011). "Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma" (PDF). Nature. 476 (7360): 298–303. Bibcode:2011Natur.476..298M. doi:10.1038/nature10351. PMC 3210554. PMID 21796119.
  10. ^ a b Ying, Carol Y.; Dominguez-Sola, David; Fabi, Melissa; Lorenz, Ivo C.; Hussein, Shafinaz; Bansal, Mukesh; Califano, Andrea; Pasqualucci, Laura; Basso, Katia (2013-10-01). "MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma". Nature Immunology. 14 (10): 1084–1092. doi:10.1038/ni.2688. ISSN 1529-2916. PMC 3954820. PMID 23974956.

Further reading

External links


This page is based on the copyrighted Wikipedia article: MEF2B. Articles is available under the CC BY-SA 3.0 license; additional terms may apply.Privacy Policy